Key points are not available for this paper at this time.
Identification of the mechanism(s) underlying the clinical response of patients with cancer treated with TA-targeted mAb is crucial to optimizing their application in the clinic and to selecting the patients most likely to benefit from their use.
Ferris et al. (Tue,) studied this question.